Pneumonia bacterial adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,001 adverse event reports that record the MedDRA preferred term Pneumonia bacterial. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 744 reports in the 12 months to June 2026 and 816 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 768 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 744 (0.1%) record this term. Reports for female patients were 40.6% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 109 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Pneumonia bacterial name as a suspect product, in order of name
Drug	Class	Reports with this term
Actemra	Interleukin-6 receptor antagonist	42
Adalimumab	Tumor necrosis factor blocker	42
Advair Hfa	Corticosteroid	25
Afinitor	Kinase inhibitor	28
Alvesco		26
Ambrisentan	Endothelin receptor antagonist	43
Amoxicillin	Penicillin-class antibacterial	25
Arikayce	Aminoglycoside antibacterial	29
Atezolizumab	Programmed death Receptor-1 blocking antibody	33
Avonex	Interferon beta	31
Azacitidine	Nucleoside metabolic inhibitor	41
Azathioprine	Purine antimetabolite	83
Azithromycin	Macrolide antimicrobial	44
Bamlanivimab		26
Baricitinib	Janus kinase inhibitor	25
Basiliximab	Interleukin-2 receptor blocking antibody	54
Bendamustine		56
Bortezomib	Proteasome inhibitor	61
Busulfan	Alkylating drug	59
Cabometyx	Kinase inhibitor	26
Carboplatin	Platinum-based drug	118
Carfilzomib	Proteasome inhibitor	34
Ceftriaxone	Cephalosporin antibacterial	27
Certolizumab pegol	Tumor necrosis factor blocker	29
Ciclosporin		33
Cisplatin	Platinum-based drug	73
Cosentyx	Interleukin-17A antagonist	32
Cyclophosphamide	Alkylating drug	337
Cyclosporine	Calcineurin inhibitor immunosuppressant	163
Cytarabine	Nucleoside metabolic inhibitor	100
Daratumumab	CD38-directed cytolytic antibody	49
Dexamethasone	Corticosteroid	281
Docetaxel	Microtubule inhibitor	28
Doxorubicin	Anthracycline topoisomerase inhibitor	101
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	45
Dupixent	Interleukin-4 receptor alpha antagonist	88
Enbrel	Tumor necrosis factor blocker	126
Enhertu		40
Etoposide	Topoisomerase inhibitor	108
Everolimus	Kinase inhibitor	31
Fludarabine	Nucleoside metabolic inhibitor	71
Fludarabine phosphate	Nucleoside metabolic inhibitor	38
Fluorouracil	Nucleoside metabolic inhibitor	31
Ganciclovir	Cytomegalovirus nucleoside analog DNA polymerase inhibitor	29
Gemcitabine	Nucleoside metabolic inhibitor	37
Human immunoglobulin g	Human immunoglobulin G	100
Humira		194
Ibrutinib (form s4)	Kinase inhibitor	27
Imbruvica	Kinase inhibitor	55
Imfinzi	Programmed death Ligand-1 blocker	44
Inflectra	Tumor necrosis factor blocker	81
Infliximab	Tumor necrosis factor blocker	79
Jakafi	Janus kinase inhibitor	26
Keytruda	Programmed death Receptor-1 blocking antibody	211
Leflunomide	Antirheumatic agent	37
Lenalidomide	Thalidomide analog	85
Levofloxacin	Fluoroquinolone antibacterial	45
Mepolizumab	Interleukin-5 antagonist	61
Meropenem	Penem antibacterial	73
Methotrexate	Folate analog metabolic inhibitor	271
Methotrexate sodium	Folate analog metabolic inhibitor	40
Methylprednisolone	Corticosteroid	198
Mycophenolate mofetil	Antimetabolite immunosuppressant	390
Mycophenolic acid	Antimetabolite immunosuppressant	33
Nivolumab	Programmed death Receptor-1 blocking antibody	84
Obinutuzumab	CD20-directed cytolytic antibody	31
Ocrevus	CD20-directed cytolytic antibody	41
Ofev	Kinase inhibitor	51
Opdivo	Programmed death Receptor-1 blocking antibody	135
Opsumit	Endothelin receptor antagonist	60
Orencia	Selective T cell costimulation modulator	28
Oxaliplatin	Platinum-based drug	57
Paclitaxel	Microtubule inhibitor	67
Pembrolizumab	Programmed death Receptor-1 blocking antibody	34
Pomalyst	Thalidomide analog	45
Prednisolone	Corticosteroid	330
Prednisone	Corticosteroid	405
Predonine		55
Prograf	Calcineurin inhibitor immunosuppressant	71
Remdesivir	SARS-CoV-2 nucleotide analog RNA polymerase inhibitor	52
Remicade	Tumor necrosis factor blocker	121
Revlimid	Thalidomide analog	175
Rheumatrex		45
Rinvoq	Janus kinase inhibitor	70
Rituxan	CD20-directed cytolytic antibody	35
Rituximab	CD20-directed cytolytic antibody	433
Simponi	Tumor necrosis factor blocker	120
Sirolimus	Kinase inhibitor	39
Skyrizi	Interleukin-23 antagonist	34
Symbicort	Corticosteroid	31
Tacrolimus	Calcineurin inhibitor immunosuppressant	373
Thymocyte Immune Globulin		29
Thymoglobulin	Immunoglobulin G	28
Tiotropium bromide	Anticholinergic	25
Tocilizumab	Interleukin-6 receptor antagonist	290
Tysabri	Integrin receptor antagonist	29
Uptravi	Prostacyclin receptor agonist	45
Vancomycin	Glycopeptide antibacterial	53
Vedolizumab	Integrin receptor antagonist	41
Veklury	SARS-CoV-2 nucleotide analog RNA polymerase inhibitor	29
Velcade	Proteasome inhibitor	47
Venclexta	BCL-2 inhibitor	46
Venetoclax	BCL-2 inhibitor	60
Vincristine		122
Vincristine sulfate	Vinca alkaloid	27
Voriconazole	Azole antifungal	39
Xeljanz	Janus kinase inhibitor	65
Xolair	Anti-IgE	39
Yervoy	CTLA-4-directed blocking antibody	51

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 46 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Pneumonia bacterial name, in order of name
Class	Reports with this term
Alkylating drug	498
Aminoglycoside antibacterial	54
Anthracycline topoisomerase inhibitor	156
Anti-IgE	53
Anticholinergic	52
Antimetabolite immunosuppressant	448
Atypical antipsychotic	76
Azole antifungal	77
BCL-2 inhibitor	106
Calcineurin inhibitor immunosuppressant	632
CD20-directed cytolytic antibody	592
CD38-directed cytolytic antibody	87
Cephalosporin antibacterial	58
Complement inhibitor	61
Corticosteroid	1,369
CTLA-4-directed blocking antibody	79
Endothelin receptor antagonist	142
Factor Xa inhibitor	55
Fluoroquinolone antibacterial	69
Folate analog metabolic inhibitor	354
Glycopeptide antibacterial	62
Human immunoglobulin G	136
Integrin receptor antagonist	79
Interleukin-2 receptor blocking antibody	54
Interleukin-23 antagonist	50
Interleukin-4 receptor alpha antagonist	100
Interleukin-5 antagonist	84
Interleukin-6 receptor antagonist	362
Janus kinase inhibitor	228
Kinase inhibitor	491
Macrolide antimicrobial	67
Microtubule inhibitor	117
Nucleoside metabolic inhibitor	396
Penem antibacterial	75
Penicillin-class antibacterial	56
Platinum-based drug	248
Programmed death Ligand-1 blocker	53
Programmed death Receptor-1 blocking antibody	520
Prostacycline vasodilator	80
Proteasome inhibitor	179
Proton pump inhibitor	61
Purine antimetabolite	99
SARS-CoV-2 nucleotide analog RNA polymerase inhibitor	81
Thalidomide analog	328
Topoisomerase inhibitor	127
Tumor necrosis factor blocker	636

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Pneumonia bacterial, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Pneumonia bacterial
Age	Reports	Share
Under 2	77	0.9%
2 to 11	160	1.8%
12 to 17	79	0.9%
18 to 44	801	8.9%
45 to 64	1,997	22.2%
65 to 74	1,858	20.6%
75 and over	1,574	17.5%
Age not given	2,455	27.3%

Sex of the patient in the reports that record Pneumonia bacterial
Sex	Reports	Share
Female	3,650	40.6%
Male	4,030	44.8%
Unknown or not given	1,321	14.7%

Age and sex are as the report gives them. 33.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Pneumonia bacterial: adverse event reports that record this term. https://reportedreactions.com/reaction/pneumonia-bacterial/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Pneumonia bacterial mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page